Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2025 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
September 02, 2025 08:00 ET | Source: KALA BIO, Inc.

KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
September 02, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc.

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment...
September 02, 2025 08:00 ET | Source: BellRing Brands, Inc.

BellRing Brands Announces New Share Repurchase Authorization of $400 Million

ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) today announced its Board of Directors approved a $400 million share repurchase authorization over the next two years...
September 02, 2025 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company...
September 02, 2025 08:00 ET | Source: OMass Therapeutics

OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel diseaseOMass to receive $20 million...
September 02, 2025 07:50 ET | Source: Fundamental Global Inc.

Fundamental Global Inc.’s CEO of Digital Assets, Maja Vujinovic, to Join Anchorage Digital’s Livestream on September 3, 2025

Charlotte, NC, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fundamental Global Inc (Nasdaq: FGNX, FGNXP) (the “Company” or “FG Nexus”) today announced that Maja Vujinovic, CEO of Digital Assets, will join...
September 02, 2025 07:30 ET | Source: Dragonfly Energy Holdings Corp.

Dragonfly Energy Announces Updated Corporate Presentation

RENO, Nev., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology,...
September 02, 2025 07:30 ET | Source: ASP Isotopes Inc.

ASP Isotopes Issues Letter to Shareholders

WASHINGTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and...
September 02, 2025 07:30 ET | Source: CorMedix, Inc.

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

- Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue...